News

Ensitrelvir Fumaric Acid (S-217622), a Therapeutic Drug for COVID-19, Shows High In Vitro Antiviral Activity Against Omicron Subvariants BA.2.75

S-217622, a Therapeutic Drug for COVID-19, Shows High In Vitro Antiviral Activity Against Omicron Subvariants BA.4 And BA.5

Notice Regarding the Launch of the new SHIONOGI Group Brand

Shionogi, GARDP and CHAI Announce Landmark License and Collaboration Agreements To Treat Bacterial Infections by Expanding Access to Cefiderocol in 135 Countries

Shionogi Announces Strategic Re-Organization of U.S. Executive Leadership

New Data for Shionogi’s COVID-19 Once-Daily Oral Antiviral S-217622 Show Rapid Virus Clearance

ACTG and Shionogi Announce Progress on Global Phase 3 Trial of Novel COVID-19 Oral Antiviral Agent S 217622

Shionogi Provides Humanitarian Aid to Ukraine

Shionogi Files for Approval of S-217622, a Therapeutic Drug for COVID-19, in Japan

Shionogi Presents Phase 2/3 Clinical Trial Results (Phase 2a Part) for the COVID-19 Therapeutic Drug S-217622